HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
about
Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.Heat shock protein antagonists in early stage clinical trials for NSCLC.A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.The HSP90 chaperone machinery.
P2860
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
HSP90 Inhibitor-SN-38 Conjugat ...... omerase I Inhibitor to Tumors.
@en
type
label
HSP90 Inhibitor-SN-38 Conjugat ...... omerase I Inhibitor to Tumors.
@en
prefLabel
HSP90 Inhibitor-SN-38 Conjugat ...... omerase I Inhibitor to Tumors.
@en
P2093
P1476
HSP90 Inhibitor-SN-38 Conjugat ...... omerase I Inhibitor to Tumors.
@en
P2093
Chaohua Zhang
David A Proia
Dinesh Chimmanamada
Donald L Smith
Igor Astsaturov
Jaime Acquaviva
John-Paul Jimenez
Junyi Zhang
Luisa Shin Ogawa
P304
P356
10.1158/1535-7163.MCT-15-0455
P577
2015-08-13T00:00:00Z